title: Retroviral transduction of murine and human hematopoietic progenitors and stem cells.
abstract: Genetic modification of cells using retroviral vectors is the method of choice when the cell population is difficult to transfect and/or requires persistent transgene expression in progeny cells. There are innumerable potential applications for these procedures in laboratory research and clinical therapeutic interventions. One paradigmatic example is the genetic modification of hematopoietic stem and progenitor cells (HSPCs). These are rare nucleated cells which reside in a specialized microenvironment within the bone marrow, and have the potential to self-renew and/or differentiate into all hematopoietic lineages. Due to their enormous regenerative capacity in steady state or under stress conditions these cells are routinely used in allogeneic bone marrow transplantation to reconstitute the hematopoietic system in patients with metabolic, inflammatory, malignant, and other hematologic disorders. For patients lacking a matched bone marrow donor, gene therapy of autologous hematopoietic stem cells has proven to be an alternative as highlighted recently by several successful gene therapy trials. Genetic modification of HSPCs using retrovirus vectors requires ex vivo manipulation to efficiently introduce the new genetic material into cells (transduction). Optimal culture conditions are essential to facilitate this process while preserving the stemness of the cells. The most frequently used retroviral vector systems for the genetic modifications of HSPCs are derived either from Moloney murine leukemia-virus (Mo-MLV) or the human immunodeficiency virus-1 (HIV-1) and are generally termed according to their genus gamma-retroviral (γ-RV) or lentiviral vectors (LV), respectively. This chapter describes in a step-by-step fashion some techniques used to produce research grade vector supernatants and to obtain purified murine or human hematopoietic stem cells for transduction, as well as follow-up methods for analysis of transduced cell populations.
authors: Boston Children's Hospital, Dana Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, 300 Longwood Ave., Karp 08125.3, 02115, Boston, MA, USA.
authors: Marioara F
authors: MF
authors: Ciuculescu
authors: Christian
authors: C
authors: Brendel
authors: Chad E
authors: CE
authors: Harris
authors: David A
authors: DA
authors: Williams
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D001854:Bone Marrow Cells / Q000166:cytology; D002130:Calcium Phosphates / Q000737:chemistry; D002460:Cell Line; D002469:Cell Separation; D005472:Fluorouracil / Q000494:pharmacology; D005822:Genetic Vectors / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D051379:Mice; D011094:Polyethyleneimine / Q000737:chemistry; D012190:Retroviridae / Q000235:genetics*; D014161:Transduction, Genetic / Q000379:methods*; D014162:Transfection
chemical_list: D018952:Antigens, CD34; D002130:Calcium Phosphates; D011094:Polyethyleneimine; C020243:calcium phosphate; D005472:Fluorouracil